Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model

Mary A. Banevicius¹, Nachum Kaplan², Barry Hafkin², David P. Nicolau¹

¹Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA, ²Affinium Pharmaceuticals, Inc., Toronto, ON, Canada

AFN-1252, a new antimicrobial agent, specifically and potently inhibits fatty acid synthesis in Staphylococcus aureus. We characterized in vivo pharmacokinetic and pharmacodynamic profiles of AFN-1252 administered orally to neutropenic mice inoculated in thighs (~10⁶ CFU) with methicillin-susceptible S. aureus (MSSA) ATCC 29213. Efficacy was also assessed in mice inoculated with MSSA, hospital-acquired Methicillin-resistant Staphylococcus aureus (HA-MRSA) or community-acquired (CA)-MRSA, and administered AFN-1252 or linezolid orally. Bacterial density was determined after 24 hours and efficacy defined as the change in CFU/thigh versus untreated controls at time 0. With MSSA, antibacterial reductions of ≥1 log were observed at ≥20 mg/kg doses, with \( \frac{AUC}{MIC} \) best describing the pharmacodynamic profile of AFN-1252. The 80, 50 and 5% maximum effects were observed with \( \frac{AUC}{MIC} \) values of 22.3, 17.0, and 9.6, respectively. Similar values were obtained for CA-MRSA and HA-MRSA. AFN-1252 was 4–40 fold more effective than linezolid against CA-MRSA and HA-MRSA. These data demonstrate the excellent in vivo potency of AFN-1252 against phenotypically diverse S. aureus.

Keywords: AFN-1252, S. aureus, Efficacy, PK/PD, Murine

Introduction

Methicillin-resistant Staphylococcus aureus (MRSA) has long been recognized as a major nosocomial pathogen in healthcare facilities. Over the past decade, new forms of MRSA fully capable of causing catastrophic disease in persons without established risk factors for hospital-acquired (HA)-MRSA, have been frequently transmitted in the community.¹⁻⁴ The success of S. aureus as a pathogen rests partly with its broad virulence characteristics, its ability to cause a wide range of infections and its increasing resistance to many commonly utilized antimicrobial agents.⁵

AFN-1252 is a new antimicrobial with a new and unique mechanism of action based on the inhibition of bacterial fatty acid synthesis. It is currently in clinical development by Affinium Pharmaceuticals (Toronto, ON, Canada and Austin, TX, USA), as an oral and intravenous agent directed at both drug-susceptible and -resistant staphylococci.⁶,⁷

The pharmacokinetics pharmacodynamics and efficacy of AFN-1252 against S. aureus in the murine thigh infection model has been investigated. The first objective of these studies was to define the in vivo pharmacokinetic and pharmacodynamic profiles of AFN-1252 with methicillin-susceptible S. aureus (MSSA) strain ATCC 29213. The second objective was to assess the quantitative efficacy of AFN-1252 in a comparative single-dose response study with HA-MRSA and community-acquired MRSA (CA-MRSA).

Materials and Methods

Antimicrobial agents

AFN-1252 (Affinium Pharmaceuticals, Toronto, ON, Canada) as tosylate anhydrate (lot GJP-F-49(5)) was used in Study 1 and as tosylate monohydrate (lot A280-10-2) in Study 2. All AFN-1252 doses and concentrations were calculated, analyzed and reported as free base equivalents based on the relevant certificate of analysis. For the in vitro studies [determinations of minimum inhibitory concentrations (MICs) and protein-binding], AFN-1252 was solubilized in 100% dimethyl sulfoxide (DMSO) and...
further diluted in DMSO until the desired AFN-1252 stock solutions were achieved. The final diluent was cation-adjusted Mueller Hinton broth for MIC testing, and mouse plasma and plasma ultrafiltrate for protein-binding studies. For the pharmacokinetic and efficacy studies in vivo, a vehicle of 80% polyethylene glycol 400 (PEG 400 and water in a 4:1 ratio) was used. Commercially available linezolid (Pharmacia & Upjohn Company, Kalamazoo, MI, USA) was reconstituted in sterile water according to the manufacturer’s specifications and the suspension administered orally as the comparator compound.

**Bacterial isolates and susceptibilities**

MSSA ATCC 29213 was used for in vitro and in vivo testing in both studies. Affinium Pharmaceuticals supplied one strain each of CA-MRSA (No. 32, CDC type USA300, PVL-positive) and of HA-MRSA (No. 63, CDC type USA100, PVL-negative) for MIC determination and efficacy assessment in Study 2. For all three isolates, MICs of a panel of antimicrobials were determined in triplicate by broth microdilution in accordance with CLSI guidelines.

**Protein-binding studies**

Plasma protein-binding studies for AFN-1252 were conducted in triplicate using the ultrafiltration method as follows. A master stock solution of AFN-1252 was prepared in 100% DMSO, and secondary stock solutions were prepared in 50% DMSO at 200 times the final concentrations required for the assay. A final 1:200 dilution was performed in freshly collected mouse plasma to give concentrations of 2, 1, 0.75, 0.5, and 0.1 μg/ml. Each of the plasma/drug solutions was heated in a shaking water bath at 37°C for 10 minutes. Exactly 0.9 ml of the plasma samples were transferred in triplicate to the Amicon Centrifree® Micropartition devices (30 000 MW cut-off filter; Millipore, Bedford, MA, USA) and the filters centrifuged at 1000g at 10°C for 30 minutes. Non-specific binding of AFN-1252 to the filter device was determined with the ultrafiltrate matrix at 0.75 μg/ml. Concentrations of AFN-1252 in the plasma solutions and ultrafiltrates were determined by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.

**Thigh infection model**

Specific pathogen-free female ICR mice weighing approximately 25 g were obtained from Harlan Sprague Dawley, Inc. (Indianapolis, IN, USA). The animals were maintained and utilized in accordance with National Research Council recommendations and were provided food and water ad libitum. Mice were rendered neutropenic by intraperitoneal injections of cyclophosphamide at 150 mg/kg 4 days before inoculation and 100 mg/kg 1 day before inoculation. A bacterial suspension of approximately 10^6 CFU/ml in 0.9% sodium chloride was prepared from a 24-hour blood agar plate of each isolate. Final inoculum concentrations were confirmed by serial dilutions and plating techniques. Thigh infection was produced by injecting 0.1 ml of the inoculum into each mouse thigh 2 hours before starting antimicrobial therapy.

**Efficacy as assessed by bacterial density**

At 0 hour, i.e. 2 hours after injection of *S. aureus* into the thighs, 0.2 ml of AFN-1252 suspension or linezolid solution was administered by oral gavage to the animals (three mice per treatment group). For each experiment, one control group of three mice received drug-free vehicle in the same volume and schedule as the active drug regimen. At the same time, a group of three untreated control mice were killed for determination of bacterial counts.

In Study 1, AFN-1252 was given in 20 different treatment regimens, ranging from 5 to 400 mg/kg given 1 to 4 times daily, to animals inoculated with the MSSA strain. Additionally, to assist with the determination of the best pharmacodynamic parameter, dose fractionation studies were undertaken. Six treatment groups were administered total daily doses of 10 or 20 mg/kg as either a single, twice daily or four times daily regimen.

For studies with CA-MRSA and HA-MRSA, AFN-1252 and linezolid as a comparator were administered as single doses by oral gavage of 1, 2.5, 10, 40, 100, or 300 mg/kg (Study 2).

Untreated controls and treated animals were killed at 24 hours after dosing (the first dose if multiple dosing). Animals were euthanized by CO₂ inhalation and cervical dislocation. After the animals were killed, both thighs were removed and individually homogenized in normal saline. Serial dilutions were plated on trypticase soy agar with 5% sheep blood for CFU determinations. Efficacy (change in bacterial density) was calculated by subtracting the mean log₈₀ CFU per thigh of the untreated control mice at 0 hour from the log₁₀ CFU per thigh of each treated mouse at the end of 24 hours of therapy.

**Pharmacokinetics**

The pharmacokinetic studies of AFN-1252 were performed in mice inoculated with the MSSA strain as described above. In Study 1, single oral doses of AFN-1252 at 2.5, 5, 10, 30, and 100 mg/kg in 0.2 ml volumes were administered by gavage at 0 hour (i.e. 2 hours after inoculation). In Study 2, AFN-1252 was administered in the same manner with doses of 2.5, 5, 10, 20, 75, and 100 mg/kg. Blood samples were collected by intracardiac puncture from six mice per time point at eight time points (0.25, 0.5, 1, 2, 4, 8, 12, and 24 hours) for each regimen. Blood samples were placed in tubes containing sodium heparin and separated; plasma samples were stored at −80°C until assayed.
AFN-1252 concentrations in the murine plasma samples were determined by Charles River Laboratories Preclinical Services Montreal Inc., using a fully GLP-validated LC-MS/MS method. The internal standard was provided by Afininium Pharmaceuticals. The reference standards covered a range from 2 to 1000 ng/ml. Quality control samples of 6, 600, and 900 ng/ml were prepared in blank mouse plasma. The coefficient of variation for the calibration standards was ≤5%.

Pharmacokinetic parameters (AUC_{0-24}, C_{max}, T_{max} and t\text{1/2}) for the composite data (i.e. six mice at each time point) of each dose were calculated using a one-compartment, first-order elimination model (WinNonlin Professional version 5.0.1, Pharsight Corporation, Mountain View, CA, USA). Compartmental selection was based on visual inspection of the fit, correlation between observed and calculated concentrations, and the numerization of the Akaike's goodess of fit criteria. Parameters obtained from the single dose studies were utilized to predict the drug exposures of the multiple dose regimens for that dosage. For doses without a confirmed pharmacokinetic profile, the exposure was estimated using the mean parameter values (Table 2) of the dose above and below the dose of interest. For doses of <2.5 mg/kg or >100 mg/kg, exposure estimates were constructed using the parameters derived from the closest dose undertaken in the pharmacokinetic studies. The free concentration–time profile for each regimen was calculated using a protein-binding value of 98.5%.

Pharmacodynamics
The pharmacodynamic profile (i.e. fAUC, fC_{max} and fT_{\geq MIC}) of each dose was constructed for each of the test organisms. The change in bacterial density in thighs, expressed as change in log_{10} CFU, for both treated and untreated animals were reported using descriptive statistics. Spearman’s rank correlation coefficient was used to evaluate the relationship between fAUC, fC_{max} and fT_{\geq MIC} values and bacterial eradication. The relationship between these variables was further evaluated on WinNonlin with PD Model 108 inhibitory effect sigmoid T_{max} model. Visual inspection of the predicted line, correlation coefficient and numerization of Akaike’s criteria factored in selection of weight of the data. The same weight was utilized for each pharmacodynamic index. The pharmacodynamic index that best correlated with efficacy was determined by the highest coefficient of determination (r²) from composite plots of the free drug pharmacodynamic indices, as well as the dose fractionation studies.

Results
In vitro susceptibility
AFN-1252 exhibited MICs of 0.004 to 0.008 μg/ml against the three strains of S. aureus (Table 1). This level of activity was at least 32-fold greater than other antibacterials tested and at least 500-fold greater than linezolid.

Protein binding and pharmacokinetic studies
The protein-binding of AFN-1252 (Study 1) was 98.5±0.35% over a concentration range of 0.1 to 2 μg/ml. These studies revealed no concentration-dependent binding for this compound. Non-specific protein binding to the filter apparatus was not observed.

The PK profile displayed non-linear exposures as emphasized by the displayed fAUC, fC_{max} and T_{max}, while the half-life remains constant (Table 2, Fig. 1). The pharmacokinetic profile of AFN-1252 determined in Study 2 was similar (data not shown).

Efficacy as assessed by bacterial density with the MSSA strain (Study 1)
For the dose exposure and fractionation studies of AFN-1252, there was excellent recovery of the MSSA strain from infected thighs. At the initiation of
treatment (0 hour) bacterial densities ranged from 5.67 to 5.87 log CFU/thigh. The mean increase in bacterial density among untreated control animals at 24 hours was 2.40 ± 0.11 log CFU/thigh.

The dose-response relationships for AFN-1252 with the MSSA strain are presented in Fig. 2. A reduction in MSSA growth rate began at 5 mg/kg. Reductions in total bacterial count of 1 log and greater, compared to time 0, were observed at doses of ≥ 20 mg/kg. For dose ranging studies with MSSA, significant correlations ($r^2$ values of 0.7917 to 0.9692) were observed for the $f_{\text{AUC/MIC}}$, $T_{>\text{MIC}}$, and $f_{C_{\text{max}}/\text{MIC}}$ (Figs. 3–5). While the $f_{\text{AUC/MIC}}$ had the highest correlation, $T_{>\text{MIC}}$ was also very well correlated.

In an attempt to further determine the pharmacodynamic driver of efficacy, dose fractionation studies were undertaken. Dose fractionation of the 10 and 20 mg/kg doses demonstrated antibacterial effects with no clear advantage of increased $f_{C_{\text{max}}/\text{MIC}}$ (range studied 1.5–2.4) or $f_{T_{>\text{MIC}}}$ (range studied 24–92), thus further suggesting that $f_{\text{AUC/MIC}}$ (range studied 18–44) is the predominant parameter related to efficacy (Fig. 6). While the achievement of wide ranging $f_{C_{\text{max}}/\text{MIC}}$ values is hampered by the solubility of the compound, the composite curve (Fig. 3) displays the enhanced fit with $f_{\text{AUC/MIC}}$. The 80% (ED₈₀), 50% (ED₅₀) and 5% (ED₅) maximally effective exposures were observed with $f_{\text{AUC/MIC}}$ values of 22.3, 17.0, and 9.6, respectively.

Efficacy as assessed by bacterial density with CA-MRSA and HA-MRSA (Study 2)
At the beginning of treatment (0 hour), the bacterial densities ranged from 5.69 to 5.78 CFU/thigh for CA-MRSA and from 5.75 to 5.76 CFU/thigh for HA-MRSA. The mean increase in bacterial density among untreated control animals at 24 hours was...
1.93 to 2.43 CFU/thigh for CA-MRSA and 2.17 to 2.33 for HA-MRSA.

With CA-MRSA, AFN-1252 growth suppression began at the 2.5 mg/kg dose. Marked reduction in bacterial count, relative to time 0, was seen at a dose of ≥10 mg/kg. With linezolid, some suppression of growth was seen at 10 and 40 mg/kg, but doses of ≥300 mg/kg were required for consistent reductions in CFU (Fig. 7). Statistical differences in CFU between the two compounds were seen at doses of 2.5 and 40 mg/kg.

With HA-MRSA, the AFN-1252 antibacterial effects were comparable to that observed with CA-MRSA. Reductions in CFU/thigh of >1 log were noted with AFN-1252 doses ≥10 mg/kg, whereas doses of ≥300 mg/kg were required for similar effect by linezolid (Fig. 8). Statistical differences in log CFU between the test compounds were seen at doses of 1, 10, 40, and 300 mg/kg.

The 80, 50 and 5% maximally effective mg/kg doses for the CA-MRSA and HA-MRSA isolates were between 4 and 20 times lower for AFN-1252 compared with linezolid. Similar to the pharmacodynamic correlations reported for the MSSA using the full dose-response curve, fAUC/MIC also appears to be the best correlated index for CA-MRSA and HA-MRSA (data not shown). Table 3 summarises the fAUC/MIC of AFN-1252 required to achieve various efficacy assessments for CA-MRSA, HA-MRSA and MSSA.

Discussion

The literature is replete with evidence of the clinical sequela associated with skin infection due to S. aureus; moreover the emergence of antibiotic resistance in a great many isolates derived in both the hospital and community setting continues to challenge the clinician.1–4 As a result of this organism’s
evolutionary propensity to finding new and frequent means of acquiring antibiotic resistance and the prominence of this etiologic agent in a wide range of infections, new antimicrobials with novel mechanisms of action are required.

A one-compartment model best characterized the free concentration-time profile of AFN-1252 in murine plasma (Study 1). AFN-1252 is characterized as a Class 2 compound on the Biopharmaceutics Classification System, possessing high permeability but low aqueous solubility.11,12 Following oral administration of the AFN-1252 suspension, rapid absorption, which is limited by the rate of compound dissolution, occurs along the entire gastrointestinal tract. As higher doses of the drug are administered, a smaller proportion of soluble drug is available, resulting in non-linear exposures as was noted in the PK profile with increasing doses. While non-linearity has been observed due to the nature of the compound under study, this was taken into account in the pharmacokinetic parameter estimates (see the section on ‘Pharmacokinetics’) and therefore these parameters can be reliably utilized in PD profiling.

Herein, we report the high in vitro potency of a novel antimicrobial, AFN-1252, in comparison with other agents commonly utilized against S. aureus, including methicillin-resistant strains. Multiple studies have shown potent and specific-spectrum anti-staphylococcal activity of AFN-1252 in vitro against clinical isolates of MSSA, MRSA, and methicillin-susceptible and -resistant Staphylococcus epidermidis (MSSE and MRSE), with MIC90 values of \( \leq 0.008-0.015 \), \( \leq 0.008-0.015 \), 0.03-0.06 and \( \leq 0.008-0.03 \mu g/ml \), respectively.13,14

Our current investigation demonstrates the excellent and equivalent in vitro potency of AFN-1252 against all strains tested, including both PVL-positive and -negative MRSA strains. In addition, when similar mg/kg doses of AFN-1252 and linezolid were administered orally, AFN-1252 produced greater antibacterial effects at lower dose levels. Lastly, this study suggests that the \( \text{AUC/MIC} \) is predictive of efficacy and has also provided important evidence regarding the in vivo exposures of AFN-1252 required for antibacterial effects. AFN-1252 may well in the future become an important addition to the physician’s armamentarium in the treatment of staphylococcal infections.

Acknowledgements
This study was funded by Affinium Pharmaceuticals, Inc., Toronto, ON, Canada. Micron Research, UK, assisted in the preparation of the manuscript.

References
1 Demling RH, Waterbou H. 2007. The increasing problem of wound bacterial burden and infection in acute and chronic soft-tissue wounds caused by methicillin-resistant Staphylococcus aureus. J Burns Wounds. 2007;7:86–98.
2 Stefani S, Chung DR, Lindsay JA, Friedrich AW, Kearns AM, Westh H, et al. Methicillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents. 2012;39:273–82.
3 Mediavilla JR, Chen L, Mathema B, Kreiswirth BN. Global epidemiology of community-associated methicillin resistant Staphylococcus aureus (CA-MRSA). Curr Opin Microbiol. 2012;15:588–95.
4 Johnson AP. Methicillin-resistant Staphylococcus aureus: the European landscape. J Antimicrob Chemother. 2011;66(Suppl 4):iv43–8.
5 Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis. 1998;26:1179–81.
6 Kaplan N, Albert M, Awrey D, Bardoumitis E, Berman J, Clarke T, et al. AFN-1252 – Mode of action, in vivo activity and in vitro efficacy of a selective anti-staphylococcal FabI inhibitor. Antimicrob Agents Chemother. 2012;56:5865–74.
7 Poutanen S, Pong-Porter S, Rzayev Y, Green K, Willey B, Low D. Susceptibility of clinical S. aureus to API-1252, a novel enoyl-ACP reductase (FabI) inhibitor [abstract F1-0755]. 46th ICAAC, San Francisco, CA, Sep 2006.
8 Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 7th ed. Approved standard M7-A7. Wayne, PA: CLSI. 2006.
9 Joly-Guillou ML, Wolff M, Pocidalo JJ, Walker F, Carbon C. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the post-antibiotic effect of imipenem. Antimicrob Agents Chemother. 1997;41:345–51.
10 Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother. 1998;42:2757–9.
11 Kaplan N, Hafkin B. In vitro and in vivo absorption properties of AFN-1252, a novel specific-spectrum anti-staphylococcal agent [poster F1-2005]. 49th ICAAC, San Francisco, CA, Sep 2009.
12 Kaplan N, Flanner H, Hafkin B. Correlation of AFN-1252 Phase 0 microdosing and Phase 1 pharmacokinetics [poster F1-2006]. 49th ICAAC, San Francisco, CA, Sep 2009.
13 Karlowsky J, Laing M, Baudry T, Kaplan N, Vaughan D, Hoban D, et al. In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 2007;51:1580–1.
14 Karlowsky J, Kaplan N, Hafkin B, Hoban D, Zhanel G. APF-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. Antimicrob Agents Chemother. 2009;53:3544–8.

Table 3 Relationship between \( \text{AUC/MIC} \) and various AFN-1252 efficacy assessments for MSSA, CA-MRSA and HA-MRSA at 24 houra

| Isolate   | \( \text{ED}_{90} \) | \( \text{ED}_{50} \) | \( \text{ED}_5 \) | Stasis | –1 Log kill | \( \Delta \log \text{CFU/thigh} \) |
|-----------|-------------------|-------------------|--------------|--------|------------|-------------------|
| MSSA      | 22.3              | 17.0              | 9.6          | 19.4   | 23.6       | 3.50              |
| CA-MRSA   | 69.3              | 32.3              | 6.4          | 43.0   | 55.9       | 3.67              |
| HA-MRSA   | 32.0              | 29.4              | 4.6          | 30.0   | 33.67      | 2.63              |

Note: \(*\text{Values represent the AUC/MIC at various doses (80, 50 or 5%) of the effective dose, stasis and 1 log kill as determined by a sigmoid } E_{\text{max}} \text{ model.}\)